Side-by-side · Research reference

CJC-1295 (no DAC)vsGHK-Cu

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 1Reviewed15/51 cited

BHuman-MechanisticReviewed8/47 cited

CJC-1295 (no DAC)

Short-acting GHRH · No DAC variant

100 mcgPer doseTeichman 2006

~30 minHalf-lifeIonescu 2006

Phase 1Evidence levelTeichman 2006 Sigalos 2018

SQ · Pre-sleep · 1–2×/day

GHK-Cu

Tripeptide · Skin / Hair / Wound Healing

1–2 mgSQ dosePickart 2018

HumanMechanisticPickart 2018 Zink 2003

HoursHalf-life

SQ or topical · Local · Daily or 2-3×/week

01Mechanism of Action

Parameter

CJC-1295 (no DAC)

GHK-Cu

Primary target

Pituitary GHRH receptorTeichman 2006

Copper-dependent enzymes (lysyl oxidase, SOD); regulator of >4000 human genesPickart 2018

Pathway

GHRH-R → Gαs → cAMP → PKA → GH vesicle exocytosisTeichman 2006

Cu(II) delivery via GHK chelation → ↑collagen / elastin / GAG synthesis; ↓inflammatory cytokines; ↑hair follicle growth-factor signalingPickart 2018

Downstream effect

Pulsatile GH release matching physiological pattern; subsequent IGF-1 elevationIonescu 2006

Skin firmness + texture improvement, accelerated wound healing, hair regrowth, anti-inflammatory actionPickart 2018 Zink 2003

Feedback intact?

Yes — short pulse preserves somatostatin negative feedbackIonescu 2006

Replaces declining endogenous levels

Origin

Modified human GRF 1-29 with four substitutions (D-Ala²/Gln⁸/Ala¹⁵/Leu²⁷) for protease resistanceTeichman 2006

Endogenous tripeptide first isolated from human plasma; declines from ~200 ng/mL at age 20 to ~80 ng/mL at age 60Pickart 2018

Antibody development

Not reported in short-term studies

—

02Dosage Protocols

Parameter

CJC-1295 (no DAC)

GHK-Cu

Standard dose

100 mcg per injectionTeichman 2006

Often paired with ipamorelin in same syringe.

—

Frequency

1–2× daily (pre-sleep ± morning)

Daily or 2–3× per week (SQ)

Lower / starter dose

50 mcg per dose

0.5 mg / day SQ

Evidence basis

Phase 1 (CJC-1295 with DAC); analog dataTeichman 2006 Ionescu 2006

No-DAC variant is less studied directly; PK extrapolated from native GHRH.

Human-mechanistic + topical clinical studiesPickart 2018

Duration

8–12 weeks on / 4 off (anecdotal)

8–12 weeks for visible skin / hair effect

Reconstitution

Bacteriostatic water

Bacteriostatic water; light-protected

Timing

Pre-sleep + fasted preferred

No specific time; evening preferred for topicals

Half-life

~30 minIonescu 2006

Short pulse vs CJC-1295-DAC (~8 days). Choose no-DAC for pulsatile, DAC for sustained.

Hours (estimated; rapid tissue uptake)

Standard SQ dose

—

1–2 mg / dayPickart 2018

Anecdotal injectable range; topical creams use 0.1–2% solutions.

Topical concentration

—

0.1–2.0% in serum / cream

04Side Effects & Safety

Parameter

CJC-1295 (no DAC)

GHK-Cu

Injection site reaction

Erythema, mild pruritus

Erythema, mild pruritus (common)

Flushing / headache

Common transient effect

—

Cortisol elevation

Minimal at standard doses

—

Prolactin elevation

Minimal

—

Glucose intolerance

Possible at high cumulative doses

—

IGF-1 elevation

Dose-dependent; monitor with chronic use

—

Cancer risk

Contraindicated in active malignancy (GH/IGF-1 axis)

—

Pregnancy / OB

Avoid

Avoid topical and SQ — insufficient data

Topical irritation

—

Mild redness, transient stinging

Copper accumulation

—

Theoretical with very high chronic doses

Allergic reaction

—

Rare hypersensitivity to copper

Wilson disease

—

Contraindicated

Absolute Contraindications

CJC-1295 (no DAC)

·Active malignancy or cancer history
·Pregnancy / breastfeeding
·Disrupted hypothalamic-pituitary axis

GHK-Cu

·Wilson disease (copper-overload disorder)
·Pregnancy / breastfeeding
·Known copper hypersensitivity

Relative Contraindications

CJC-1295 (no DAC)

·Untreated diabetes
·Severe insulin resistance

GHK-Cu

·Hemochromatosis (copper-iron crosstalk theoretical)
·Concurrent copper-chelator therapy

05Administration Protocol

Parameter

CJC-1295 (no DAC)

GHK-Cu

1. Reconstitution

Add 2 mL bacteriostatic water to 2 mg vial → 1 mg/mL = 100 mcg per 0.1 mL. Roll gently.

Add 1–2 mL bacteriostatic water to a 50 mg vial → 25–50 mg/mL. Use within 30 days, refrigerated.

2. Injection site

Subcutaneous, abdomen or thigh. Rotate sites.

SQ — local to the area of interest (face, scalp) for skin / hair indications. Rotate sites.

3. Timing

Pre-sleep preferred. Often combined with ipamorelin in the same syringe.

Anytime; evening preferred. Topical: apply to clean dry skin.

4. Storage

Lyophilised: room temp, protected from light. Reconstituted: refrigerate 2–8 °C, use within 30 days.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, light-protected, ≤30 days.

5. Needle

29–31G, 4–8 mm insulin syringe.

30–31G, short (4–6 mm) for shallow SQ. Topical: clean fingertips, no needle.

06Stack Synergy

CJC-1295 (no DAC)

+ Ipamorelin

Strong

View Ipamorelin →

CJC-1295 (no DAC) and ipamorelin are the canonical "GHRH + GHRP" dual-axis stack at physiological timing. Both peak within 30 min and clear within 2 hours, producing a sharp, high-amplitude GH pulse closely resembling natural physiology. Preferred over the CJC-1295-DAC + ipamorelin stack when pulsatility (vs sustained elevation) is the goal.

CJC-1295 (no DAC): 100 mcg SQ · pre-sleep
Ipamorelin: 200–300 mcg SQ · same injection
Primary benefit: Pulsatile GH stimulation, recovery, body composition

Teichman 2006 Raun 1998

GHK-Cu

+ BPC-157

Moderate

View BPC-157 →

GHK-Cu drives ECM remodelling and copper-dependent enzymes; BPC-157 upregulates VEGFR2 angiogenesis and fibroblast migration. The pathways are non-overlapping and complementary — together they accelerate wound healing more than either alone in anecdotal protocols.

GHK-Cu: 1–2 mg SQ · daily near wound
BPC-157: 250–500 mcg SQ · daily near wound
Primary benefit: Combined ECM rebuilding + angiogenesis for tissue repair